Zimmer Biomet is in a recovery phase rather than a sustained uptrend, with a 1-year price change of -4.46% that lags the S&P 500's +13.13% by a relative strength gap of -17.59 percentage points. At the current price of $98.56, the stock sits at approximately 77.5% of its 52-week range between a low of $79.12 and a high of $104.15, meaning it has reclaimed most of its drawdown but has not yet broken out to new highs. This positioning suggests improving momentum rather than overextension, though the stock remains below its prior peak and carries a maximum drawdown of -23.47% over the measured window, a reminder of the sharp April selloff from $92.59 to $80.07 in a single session.\n\nShort-term momentum is clearly accelerating and diverging positively from the longer-term trend: the stock is up 8.45% over the past month and 7.89% over three months, versus a 1-year decline of 4.46%, and it has gained 9.49% year-to-date against a 11.45% YTD gain for SPY. The 1-month relative strength of +9.47 percentage points versus SPY is the strongest reading in the dataset, confirming that recent buying pressure is stock-specific rather than beta-driven. The move from the September 24 close of $89.69 to the October 23 close of $98.56 represents a roughly 9.9% advance in about a month, and the October 22 close of $98.81 marked the highest level since the August peak near $101.38, suggesting the pullback into late September has been fully retraced.\n\nKey technical resistance sits at the 52-week high of $104.15, roughly 5.7% above the current $98.56 price, and a decisive breakout above that level would confirm a new uptrend and likely trigger momentum-based buying. Support is anchored at the 52-week low of $79.12, about 19.7% below current levels, with intermediate support around the $88-$90 zone where the stock consolidated in late September and early October. The beta of 0.485 indicates the stock is roughly 52% less volatile than the market, which materially reduces position-sizing risk but also means the stock will likely lag in strong risk-on rallies; the short ratio of 4.74 days suggests moderate short interest that could add fuel to a breakout but is not extreme.

Revenue is growing at a modest but stable pace: Q2 2026 revenue of $2.177 billion rose 4.8% year-over-year from $2.077 billion in Q2 2025, and the trailing four-quarter revenue base of roughly $8.59 billion reflects consistent low-single-digit expansion. Sequentially, revenue moved from $2.087 billion in Q1 2026 to $2.177 billion in Q2 2026, a 4.3% increase, while the year-ago comparison of $2.077 billion confirms the growth is real rather than seasonal. Segment data shows Knees at $828.9 million, SET (surgical, extremities, trauma) at $586.0 million, and Hips at $562.7 million, meaning the knee franchise is the largest single contributor and the combined large-joint business still dominates the mix; the 4.8% growth rate is respectable for a mature orthopedics franchise but well below the double-digit growth investors typically reward with premium multiples.\n\nProfitability is solid but uneven: Q2 2026 net income was $198.3 million on a 9.1% net margin, down from $238.1 million and an 11.4% net margin in Q1 2026, and gross margin compressed from 72.4% in Q1 to 70.8% in Q2. The trailing gross margin of 61.6% in the valuation data is distorted by cost-of-revenue treatment across periods, but the quarterly gross margin trend in the low-70% range is consistent with orthopedic device peers and reflects pricing pressure in joints. Operating margin of 16.5% and EBITDA of $328 million in Q2 (a 15.1% EBITDA margin) versus $538.3 million in Q1 (25.8%) highlight meaningful quarter-to-quarter volatility, and the Q2 operating income of $326.1 million was pressured by $72.9 million of interest expense and $211.3 million of other expenses; the company remains profitable, but the margin trajectory is not yet demonstrating the operating leverage a turnaround thesis would require.\n\nThe balance sheet is reasonably healthy but not fortress-like: debt-to-equity of 0.59 and a current ratio of 1.98 provide adequate liquidity, while trailing free cash flow of $1.83 billion against a $17.8 billion market cap implies an FCF yield of roughly 10.3%, a strong cash-generation profile for a device maker. Q2 2026 operating cash flow of $447.8 million funded $116.4 million of capex and $250.7 million of buybacks, with dividends of $46.5 million, showing the company can self-fund returns; however, ROE of 5.55% and ROA of 3.88% are low for the sector, and the $1.83 billion FCF against $198.3 million of quarterly net income reflects heavy non-cash charges. Cash at the end of Q2 was $410 million, down from $591.9 million at year-end 2025, and the company repaid $30 million of debt in the quarter, suggesting deleveraging is gradual rather than aggressive.